skip to Main Content

FDA on Pfizer Booster Shot

An influential federal advisory panel overwhelmingly rejected a plan Friday to offer Pfizer booster shots against COVID-19 to most Americans, dealing a heavy blow to the Biden administration’s effort to shore up people’s protection amid the highly contagious Delta variant.

The vote by the committee of outside experts assembled by the Food and Drug Administration was 16-12, with members expressing frustration that Pfizer had provided little data on the safety of extra doses. Many also raised doubts about the value of mass boosters, rather than ones targeted to specific groups.

In an extraordinary move, both FDA leaders and the panel indicated they were likely to take a second vote Friday afternoon on recommending the booster shots for older Americans and other high-risk groups.

That would help salvage part of the Biden administration’s campaign but would still be a huge step back from the sweeping plan proposed by the White House a month ago to offer booster shots of both the Pfizer and Moderna vaccines to nearly all Americans eight months after they get their second dose.

During several hours of vigorous debate Friday, members of the panel questioned the value of offering boosters to nearly everyone.

The CDC wants to be financially prepared for the next big outbreak.

Take a listen.

“CDC is announcing a $2.1 billion American Rescue Plan to strengthen infection prevention and control activities across the US public health and health care sector. Over the next three years, CDC
will issue awards totaling $1.25 billion 64 state, local and territorial health departments to accelerate infection control efforts and invest long term in preparedness for the future.”

According to CDC Director, Dr. Walensky millions of dollars will go to beef up support for long-term care facilities and nursing homes.

The facilities can use the money to strengthen their fight against infectious diseases like COVID-19.

Back To Top